VivoSeq
Oncology

Carcinoma, Renal Cell

6

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Carcinoma, Renal Cell is an early-stage landscape with 6 programs across 6 companies. The most active players are Bristol-Myers Squibb, Merck & Co., Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Pfizer logo

Pfizer

1 program

PreclinicalP

Prism Pharmaceuticals

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody117%Vaccine117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting3 · 100%

Clinical Trials

Trial Activity

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07489495·758 enrolled
A Phase 2a Study to Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Cabozantinib in Patients With Localized Clear Cell Renal Cancer.
Recruiting·—·Phase 2·NCT05127824·42 enrolled
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Recruiting·Pfizer logoPfizer·Preclinical·NCT07227415·224 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)